The Global Liquid Biopsy market is growing at a high rate owing to the factors such as rising number of cancer cases globally, paradigm shift toward non-invasive procedures, and escalating funding for liquid biopsy research and development. Besides these , increase in sedentary lifestyle of people, burgeoning demand for liquid biopsy tests, and improving healthcare infrastructure in both developed and developing countries are strong contributing to promote the growth of the market in the forthcoming years.

However, the demand for liquid biopsy test has surged in the COVID-19 pandemic as it used to improve cancer screening. Moreover, the introduction of commercialize saliva-based liquid biopsy tests for head and neck cancer, COVID-19, by the market players is anticipated to place a positive impact toward the growth of the market in the near future.

Get the sample report at: https://www.marknteladvisors.com/query/request-sample/global-liquid-biopsy-market.html

According to MarkNtel Advisors’ research report titled “Global Liquid Biopsy Market Analysis, 2020”, the Global Liquid Biopsy market is anticipated to grow at a CAGR of around 26% during 2021-26F. Based on Disease Type, Breast Cancer acquired the substantial market share in 2020. The breast cancer is a major cause of death among women. According to WHO, 627,000 women died from breast cancer in 2018. The significant rise of breast cancer incidences is projected to fuel the demand for liquid biopsy as it is used spot breast cancer cells before a tumor starts spreading.

“Global Liquid Biopsy Market Analysis, 2020” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and growth opportunities available for Liquid Biopsy providers across the globe. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitor's capabilities on 16 parameters. This will help companies in the formulation of Go to Market Strategies and identifying the blue ocean for its offerings.

Asia-Pacific Acquired Considerable Market Share
Asia-Pacific acquired considerable market share in the Global Liquid Biopsy market in 2020. The growth of the region is attributed increasing prevalence of cancer cases, burgeoning government investment in the healthcare infrastructure, and growing awareness about minimally invasive procedures. Moreover, escalating funding on research on cancer biomarkers and on R&D activity for liquid biopsy are anticipated to bolster the growth of the Liquid Biopsy Market in the forthcoming period as stated in MarkNtel Advisors’ research report “Global Liquid Biopsy Market Analysis, 2020”.

According to MarkNtel Advisors, the key players with a considerable market share in the Global Liquid Biopsy market are Bio-Rad Laboratories, Biocept Inc, Abcodia Ltd, Chronix Biomedical, Epic Sciences Inc, Hoffmann-La Roche AG, Cynvenio Biosystems, Inc., GUARDANT HEALTH, INC, Illumina, Inc., NeoGenomics Laboratories, Inc., Menarini Silicon Biosystems, Inc., Qiagen N.V., Thermo Fisher Scientific, Personal Genome Diagnostics, Inc., Qiagen N.V. etc.

Market Segmentation:
1. By Work Process (Sample Preparation, Library Preparation, Sequencing, Data Analysis)
2. By Technology (PCR [RT-PCR, dPCR, Multiplex PCR, Others], NGS, FISH, Other Technologies)
3. By Usage (RUO, Clinical)
4. By Sample Type (Blood, Urine, Saliva, CerebroSpinal Fluid)
5. By Product (Test /Services, Kits and Consumables, Instruments)
6. By Circulating Biomarkers (Circulating Tumor Cells, Cell-free DNA, Circulating Cell-Free RNA, Exosomes and Extracellular Vesicles, Others)
7. By Disease Type (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Cancers, Non-Oncology Disorders)
8. By Clinical Application (Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening)
9. By Region (North America, South America, Europe, Asia-Pacific, Middle East & Africa)
10. By Country (US, Canada, Mexico, Brazil, UK, Germany, France, Italy, Spain, UAE, Saudi Arabia, South Africa, China, Japan, South Korea, India, South East Asia),
11. By Company (Bio-Rad Laboratories, Biocept Inc, Abcodia Ltd, Chronix Biomedical, Epic Sciences Inc, Hoffmann-La Roche AG, Cynvenio Biosystems, Inc., GUARDANT HEALTH, INC, Illumina, Inc., NeoGenomics Laboratories, Inc., Menarini Silicon Biosystems, Inc., Qiagen N.V., Thermo Fisher Scientific, Personal Genome Diagnostics, Inc., Qiagen N.V. etc.)

Key questions answered in the study:
1. What are the current and future trends of the Liquid Biopsy industry?
2. How the industry has been evolving in terms of end-user demand and application areas?
3. How the competition has been shaping across the countries followed by their comparative factorial indexing?
4. What are the key growth drivers and challenges for the Liquid Biopsy industry?
5. What is the customer orientation, purchase behavior, and expectations from the Liquid Biopsy firms across various regions?